Toxizität und Effektivität wiederholter Docetaxel­therapie des hormonrefraktären Prostatakarzinoms

Abstract

Intermittent docetaxel therapy is well tolerated and shows high response rates in the sec-ond and third sequences of treatment in select-ed HRPC patients who presented with low docetaxel toxicity, good clinical condition and responded to prior docetaxel-based treatment.